Product Information
TERBINAFINE HCL 250 MG TABLET is a generic product labeled by Chartwell RX LLC, priced at $0.1426 per EA under NDC 62135057290. Its NADAC has been published 227 times since Jun 1, 2022.
FDA first approved this application on Jul 2, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Chartwell RX LLCNDC
62135057290
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TERBINAFINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078199FDA Approved
7/2/2007
TE Code
AB
On Market Since
7/2/2007
Pharmacological Classes
Price Statistics
The NADAC for TERBINAFINE HCL 250 MG TABLET has been published 227 times since Jun 1, 2022, and over the history we have for it it has declined 10.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1426 per EA |
|---|---|
| All-time high | $0.1683 (Nov 16, 2022) |
| All-time low | $0.1158 (Nov 20, 2024) |
| 52-week high | $0.1513 |
| 52-week low | $0.1324 |
| Median price | $0.1505 |
| Average price | $0.1486 |
| Largest weekly change | -21.1% (Nov 20, 2024) |
| Weeks tracked | 227 |
| Tracking since | Jun 1, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Terbinafine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Allylamine Antifungal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TERBINAFINE HCL 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TERBINAFINE HCL 250 MG TABLET, manufactured by Chartwell RX LLC, is $0.1426 per EA (NDC 62135057290), effective Sep 30, 2026.
How has the price of TERBINAFINE HCL 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for TERBINAFINE HCL 250 MG TABLET has declined 10.1%. It has been tracked across 227 weekly CMS publications since Jun 1, 2022.
What are the highest and lowest recorded NADAC prices for TERBINAFINE HCL 250 MG TABLET?
Since Jun 1, 2022, the NADAC for TERBINAFINE HCL 250 MG TABLET has ranged from a low of $0.1158 (Nov 20, 2024) to a high of $0.1683 (Nov 16, 2022), with a median of $0.1505 per EA.
Are there cheaper alternatives to TERBINAFINE HCL 250 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TERBINAFINE HCL 250 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TERBINAFINE HCL 250 MG TABLET?
TERBINAFINE HCL 250 MG TABLET (NDC 62135057290) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.